ScholarIQanswers from OpenAlex & ORCID
Ji‐Youn Han
ResearcherPublications, citations & collaboration network
Ji‐Youn Han is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ji‐Youn Han have?
ScholarIQindexed works
Ji‐Youn Han has 492 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ji‐Youn Han have?
ScholarIQcitation count
Ji‐Youn Han has 25,653 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ji‐Youn Han?
ScholarIQh-index
Ji‐Youn Han has an h-index of 70 in OpenAlex.
What is the i10-index of Ji‐Youn Han?
ScholarIQi10-index
Ji‐Youn Han has an i10-index of 196 in OpenAlex.
What is the ORCID of Ji‐Youn Han?
ScholarIQorcid
The ORCID for Ji‐Youn Han is on the source record.
What is the OpenAlex record for Ji‐Youn Han?
ScholarIQopenalex
The OpenAlex for Ji‐Youn Han is on the source record.
What are the most-cited papers on Ji‐Youn Han?
ScholarIQmost cited works
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer
Jürgen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Toyoaki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian J. Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R. Overbeck, Filippo de Marinis, Tae Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaër, Maeve Waldron-Lynch, B. Sankaran, O. Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S. Heist
Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer
D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Jong Seok Lee, Maximilian J. Hochmair, Jacky Yu-Chung Li, Gee‐Chen Chang, Ki Hyeong Lee, Cesare Gridelli, Angelo Delmonte, Rosario García Campelo, Dong‐Wan Kim, Alessandra Bearz, Frank Griesinger, Alessandro Morabito, Enriqueta Felip, Raffaele Califano, Sharmistha Ghosh, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Neeraj Gupta, J. Haney, David Kerstein, Sanjay Popat
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
Paul K. Paik, Enriqueta Felip, Rémi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina Chiara Garassino, Julien Mazières, Santiago Viteri, Hélène Senellart, Jan P. van Meerbeeck, Jo Raskin, Niels Reinmuth, PierFranco Conte, Dariusz M. Kowalski, Byoung Chul Cho, Jyoti D. Patel, Leora Horn, Frank Griesinger, Ji‐Youn Han, Young‐Chul Kim, Gee‐Chen Chang, Chen‐Liang Tsai, James Chih‐Hsin Yang, Yuh-Min Chen, Egbert F. Smit, Anthonie J. van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, John V. Heymach, Xiuning Le
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Ji‐Youn Han, Keunchil Park, Sang‐We Kim, Ki Hyeong Lee, Hyae Young Kim, Heung Tae Kim, Myung‐Ju Ahn, Tak Yun, Jin Seok Ahn, Cheolwon Suh, Jung‐Shin Lee, Sung Jin Yoon, Jong Hee Han, Jae‐Won Lee, Sook Jung Jo, Jin Soo Lee